2017 was a record year in our Centre´s history, the CNIO published more papers than ever before in top journals with impact factor greater than 15
The CNIO is ranked seventh among all the world´s cancer research centres
According to the SCImago research group, the Spanish National Cancer Research Centre (CNIO) topped the 2017 ranking of research institutions dedicated to the health sciences. In its survey of institutions specifically dedicated to cancer research, the CNIO ranked in third place in Europe, after Cancer Research UK and the UK Cancer Research Institute. According to Nature Index, CNIO ranked second in Europe in this same category.
“The fact that CNIO is well positioned in these rankings reflects the high impact and innovation of the research conducted at this Centre. This is thanks to the tremendous quality of all CNIO researchers “, noted the director Maria A. Blasco.
According to the data compiled, in 2017, the CNIO ranked first amongst all the Spanish centres dedicated to biomedical research. And rightly so, because last year, CNIO researchers published more papers than ever before in journals with an impact factor greater than 15.
The SCImago Institutions Rankings (SIR) is generated taking into account three groups of indicators based on research, innovation, and social impact measured by their web visibility. These represent 50%, 30% and 20% of the total score, respectively.
The CNIO is a centre that is entirely dedicated to cancer research; from its most basic aspects to its clinical application in patients. Furthermore, it has a medicinal chemistry programme that covers the early stages of drug development to tackle the therapeutic targets on which its scientists are working. In recent years, the Centre has added new lines of research with the incorporation of several groups dedicated to metastasis, metabolism, and structural biology.
Compared to other institutions that concentrate solely on cancer research, the CNIO ranked in seventh place in the SCImago world ranking, and in sixth place according to the Nature Index, behind organisations such as the Dana Farber Cancer Institute and the Memorial Sloan-Kettering Cancer Center.
One of the aspects in which the Centre scored particularly high is innovation, one of CNIO’s key strategic areas. With a patent portfolio composed of more than 30 families – five of which were licensed in 2017 – and with inventors well above 10% of CNIO´s researchers, innovation has become and continues to be an intrinsic part of the CNIO culture.